Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol
- Trading Under New Ticker of “EXOZ” Expected to Begin February 12, 2025 Trading Under New Ticker of “EXOZ” Expected to Begin February 12, 2025
- 02/10/2025
|
Rethinking Diabetes Care: PatentVest Pulse Unveils Key Insights on the Expanding CGM Market and the Innovations Driving Change
- Addison, TX, Jan. 07, 2025 (GLOBE NEWSWIRE) -- PatentVest, a leader in intellectual property (IP) intelligence and strategy, has released its latest report, “Continuous Glucose Monitoring (CGM): An Evolving Innovation Landscape.” This in-depth analysis explores the rapidly growing CGM market, offering valuable insights into the trends, key players, and opportunities that are shaping the future of diabetes care.
- 01/07/2025
|
MDB Capital Holdings Provides Third Quarter 2024 Update
- Addison, TX, Nov. 21, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, today provides an update on operations through and subsequent to the quarter ended September 30, 2024. “Throughout the year, we continued to strengthen our operations to increase our capacity to curate and diligence deep technology ideas that we can ultimately finance and help stand up to become leaders in their technology category,” said Christopher Marlett, CEO and Co-Founder of MDB.
- 11/21/2024
|
Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities
- Project is part of the U.S. Department of Defense's BioMADE initiative to support U.S. bioindustrial manufacturing innovations and workforce development Project is part of the U.S. Department of Defense's BioMADE initiative to support U.S. bioindustrial manufacturing innovations and workforce development
- 11/19/2024
|
MDB Capital Holdings to Host Third Quarter 2024 Results Conference Call on Thursday November 21, 2024, at 4:30 p.m. Eastern Time
- Addison, Texas, Nov. 15, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, plans to host a Zoom webinar on Thursday November 21, 2024 at 4:30 p.m. Eastern Time to discuss its results for the third quarter 2024. A press release detailing these results will be issued prior to the call.
- 11/15/2024
|
Invizyne Technologies Announces Closing of Initial Public Offering
- Monrovia, CA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc. , a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, today announced the closing of its initial public offering of 1,875,000 shares of its common stock at a public offering price of $8.00 per share. The shares began trading on NASDAQ under the ticker symbol “IZTC” on November 13, 2024.
- 11/14/2024
|
Invizyne's Nasdaq IPO Marks New Era of Biomanufacturing
- Underlying technology demonstrates the use of enhanced enzyme systems outside of cells can bypass many of the limitations associated with traditional cell-based synthetic biology Underlying technology demonstrates the use of enhanced enzyme systems outside of cells can bypass many of the limitations associated with traditional cell-based synthetic biology
- 11/13/2024
|
Invizyne Technologies Begins Trading on NASDAQ
- Next Generation Synthetic Biology Company Will Trade Under Ticker Symbol "IZTC" Next Generation Synthetic Biology Company Will Trade Under Ticker Symbol "IZTC"
- 11/13/2024
|
Invizyne Technologies to Begin Trading on NASDAQ on November 13, 2024
- Next Generation Synthetic Biology Company Will Trade Under Ticker Symbol "IZTC" Next Generation Synthetic Biology Company Will Trade Under Ticker Symbol "IZTC"
- 11/12/2024
|
Invizyne Technologies Announces Pricing of $15 Million Initial Public Offering
- Shares to Begin Trading on NASDAQ on November 12, 2024, Under the Ticker Symbol “IZTC” Shares to Begin Trading on NASDAQ on November 12, 2024, Under the Ticker Symbol “IZTC”
- 11/11/2024
|
MDB Capital Announces Record Date and Expected Timing for Initial Public Offering for Invizyne Technologies
- Record date of July 22, 2024 set for allocation preferences Closing and trading expected on NASDAQ on or before August 15 Addison, Texas, July 11, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, today announces the record date, allocation preference, and expected timeline for the proposed offering for Invizyne Technologies, Inc. In February 2024, Invizyne – a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life and a subsidiary of MDB Capital Holdings – filed its IPO registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") for the sale of its common stock in a firm commitment public offering. The offering will be for 4,300,000 shares of common stock at a price per share of $4.00, for gross proceeds of $17.2 million.
- 07/11/2024
|
Recently Published Whitepaper from PatentVest Delves into Transformative Innovations in MASH Diagnostics
- Transformative Innovations in MASH Diagnostics Dallas, Texas, July 09, 2024 (GLOBE NEWSWIRE) -- PatentVest, the first integrated IP intelligence strategy and law firm, recently published a whitepaper that presents strategic insights in the fields of Metabolic-Associated Steatohepatitis (MASH) biomarkers and Point of Care (PoC) kits for MASH diagnostics. This whitepaper serves as a valuable resource for stakeholders looking to navigate the complex and rapidly evolving landscape of these fields, offering guidance on capitalizing on innovation, collaboration, and IP protection to gain a competitive edge.
- 07/09/2024
|
MDB Capital Collaborates with Mayo Clinic to Advance Anti-Senescence Platform
- ADDISON, Texas, July 08, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, today announced a collaboration through a patent and know-how agreement with Mayo Clinic to develop a small molecule anti-senescence platform. This collaboration aims to advance research in longevity and age-related disease prevention.
- 07/08/2024
|
MDB Capital Expands Board, Appoints Daniel Torpey as New Director
- Addison, Texas, June 20, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB Capital”), a public venture platform focused on launching category-leading deep technology companies, today announced the appointment of Daniel Torpey to its Board of Directors, effective June 17, 2024.
- 06/20/2024
|
New PatentVest Pulse Report Reveals Transformative Trends in Portable ECG Monitoring
- 56% increase in global patent publications over the last five years signals growing interest in the cardiac monitoring market which is expected to grow to $3 billion per year by 2029 according to Statista. PatentVest's report provides groundbreaking insights into the evolving landscape of cardiac care, highlighting key players, technological advancements and the race for innovation.
- 05/22/2024
|
MDB Capital Holdings Unveils Unified Corporate Branding
- Addison, TX, May 22, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, today announces its self-clearing broker dealer and associated online and mobile trading platforms will now unify under one brand name, MDB Capital.
- 05/22/2024
|
Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on Nasdaq
- Michael Heltzen appointed as CEO bringing 20 years of global commercial leadership experience and a track record of successful launches and exits Additional industry veterans join in key roles including business development, finance, and communications MONROVIA, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc. , a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, today announced the appointment of Michael Heltzen as CEO, and the recent hirings of additional seasoned industry executives for its leadership team.
- 05/07/2024
|
Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on Nasdaq
- MONROVIA, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc. , a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, today announced the appointment of Michael Heltzen as CEO, and the recent hirings of additional seasoned industry executives for its leadership team.
- 05/07/2024
|
MDB Capital Holdings Year-End Update
- Addison, Texas, April 17, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, reported results for its fourth quarter and full year ended December 31, 2023, on form 10-K filed with the Securities and Exchange Commission, and will highlight recent corporate progress on today's call with management. “On the heels of completing our IPO on the NASDAQ in the third quarter of 2023, we've been working diligently to advance our self-clearing broker dealer capabilities to support our investor community, increasing the number of deep technology ideas we review and ultimately finance, as well as ramp up the number of clients engaged with our integrated IP solution platform, PatentVest, which is critical in assisting the companies we back to become leaders in their technology category,” said Christopher Marlett, CEO and Co-Founder of MDB.
- 04/17/2024
|
MDB Capital Holdings to Host Fourth Quarter 2023 and Fiscal
- Addison, Texas, April 11, 2024 (GLOBE NEWSWIRE) — MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, plans to host a Zoom webinar on Wednesday April 17, 2024 at 4:30 p.m. Eastern Time to … The post MDB Capital Holdings to Host Fourth Quarter 2023 and Fiscal appeared first on Headlines of Today...
- 04/11/2024
|
MDB Capital Holdings to Host Fourth Quarter 2023 and Fiscal Year 2023 Results Webinar on Wednesday April 17, 2024 at 4:30 PM Eastern Time
- Addison, Texas, April 11, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, plans to host a Zoom webinar on Wednesday April 17, 2024 at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter and full fiscal year ended December 31, 2023. A press release detailing these results will be issued prior to the call.
- 04/11/2024
|
MDB Capital Holdings Issues Annual Letter to Shareholders
- Addison, TX, Jan. 31, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, today released its annual letter to shareholders from its CEO and Co-Founder, Christopher Marlett.
- 01/31/2024
|
MDB Capital Holdings Reports Third Quarter 2023 Results
- Addison, TX, Nov. 15, 2023 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, yesterday reported results for its third quarter ended September 30, 2023 on form 10-Q filed with the Securities and Exchange Commission, and will highlight recent corporate progress on today's call with management.
- 11/15/2023
|
Michael Burns Joins Invizyne as Executive Vice President of Energy Transition
- Monrovia, CA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc. , a leading designer of enzyme-based biomanufacturing systems – and a subsidiary of MDB Capital Holdings, LLC , (NASDAQ:MDBH) ("MDB") – today announced the appointment of Michael Burns to its senior leadership team as Executive Vice President, Energy Transition.
- 11/08/2023
|
Invizyne Selected by Shell GameChanger Accelerator Powered by NREL for Sixth Cohort
- Non-Dilutive Funding and Resources Provided to De-Risk Investment and Accelerate Commercialization Non-Dilutive Funding and Resources Provided to De-Risk Investment and Accelerate Commercialization
- 10/17/2023
|
Invizyne Awarded Additional $3.77 Million Grant from U.S. Department of Energy
- Funding Supports Project to Optimize and Scale Up Isobutanol Production to Address Potential $27.4 Billion Sustainable Aviation Fuel Market Funding Supports Project to Optimize and Scale Up Isobutanol Production to Address Potential $27.4 Billion Sustainable Aviation Fuel Market
- 10/11/2023
|
MDB Capital Holdings Begins Trading on NASDAQ
- Public Venture Platform Company Will Trade Under Ticker Symbol "MDBH" ADDISON, TX / ACCESSWIRE / September 21, 2023 / MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB") a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, today announced it raised $19,999,992 and is pleased to announce that its Class A Common Shares representing MDB limited liability interests will begin trading on the NASDAQ today, September 21, 2023 at approximately 10:45am EST under the ticker symbol "MDBH." About MDB Capital Holdings, LLC MDB was founded in 1997 with the purpose of backing visionary technology, inventors, and technology entrepreneurs via a new form of public venture capital that finances pre-revenue, early-stage companies through early public offerings, primarily listed on NASDAQ.
- 09/21/2023
|